Clinical and epidemiological features of neuroendocrine tumors on basis of single-centre registry
https://doi.org/10.33667/2078-5631-2022-5-7-14
Abstract
Neuroendocrine tumors (NET) are fairly heterogenous malignant tumors. The algorithm of choosing a particular type of treatment, including systemic therapy, depends on the degree of differentiation and tumor burden based on the WHO classification (2010) and the guidelines of the European Neuroendocrine Tumor Society (ENETS, 2011). This nosology is relatively rare (the incidence is 2 to 5 per 100 thousand population).
However, over the past 30 years, there has been an increase in the number of NET diseases by 720 % according to the US SEER (Surveillance, Epidemiology, and End Results) register. This article presents the results of the analysis of the clinical and epidemiological characteristics of neuroendocrine gastrointestinal tumors in patients treated in the St. Petersburg City Clinical Oncology Centre.
About the Authors
A. V. Androsova
Saint Petersburg State University; City Clinical Oncology Centre
Russian Federation
Russian Federation
Androsova Aleksandra V., post-graduate student, medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10
R. V. Orlova
Saint Petersburg State University; City Clinical Oncology Centre
Russian Federation
Russian Federation
Orlova Rashida V., DM Sci. (habil.), head of Chair for Oncology, chief specialist in Clinical Oncology
Saint Petersburg
SPIN: 3480–2098.
Author ID: 40117
A. K. Ivanova
City Clinical Oncology Centre
Russian Federation
Russian Federation
Ivanova Anastasia K., medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Dept No. 11
Saint Petersburg
N. P. Belyak
Saint Petersburg State University; City Clinical Oncology Centre
Russian Federation
Russian Federation
Belyak Natalia P., PhD Med, associate professor at Dept of Oncology, head of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10
Saint Petersburg
SPIN: 2937–4858
Author ID: 778562
S. I. Kutukova
City Clinical Oncology Centre; First Saint Petersburg State Medical University n. a. I. P. Pavlov
Russian Federation
Russian Federation
Kutukova Svetlana I., PhD Med, associate professor at Dept of Surgical and Maxillofacial Surgery Dentistry, medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10
Saint Petersburg
SPIN: 6735–6556
Author ID: 698363
E. A. Kaledina
City Clinical Oncology Centre
Russian Federation
Russian Federation
Kaledina Ekaterina A., medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10
Saint Petersburg
SPIN: 8925–3320
Author ID: 1020115
References
1. Yao J. C., Hassan M., Phan A., Dagohoy C. et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008. 26 (18). Р: 3063–3072. DOI: 10.1200/JCO.2007.15.4377.
2. Modlin I. M., Moss S. F., Chang D. C. et al. Priorities for improving the management of gastroenteropancreatic neruoendocrine tumors. J. Natl. Cancer Inst. 2008. 100 (18). Р: 1282–1289. DOI: 10.1093/jnci/djn275.
3. Oberg K., Modlin I. Carcinoid Tumors – Current Considerations in a Century of Advances in Neuriendocrine Tumor. In: Biology and Treatment. 2007. P: 40–53.
4. Rinke A., Wittenberg M., Schade-Brittinger C., Aminossadati B., Ronicke E., Gress T. M. (PROMID Study Group). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2017. 104 (1). P: 26–32. DOI: 10.1159/000443612.
5. Rinke A., Muller H. H., Schade-Brittinger C., Klose K. J., Barth P., Wied M. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009. 27 (28). P: 4656–4663.
6. Lee A., Chan D. L., Wong M. H., Li B. T., Lumba S., Clarke S. J. et al. Systematic review of the role of targeted therapy in metastatic neuroendocrine tumors. Neuroendocrinology. 2017. 104 (3). P. 209–222. DOI: 10.1159/000446115.
7. Öberg K. lnterferon-α versus Somatostatin or the Combination of Both in Gastro-Enteropancreatic Tumours. Digestion. 1996. 57 (Suppl. 1). P. 81–83. https://doi.org/10.1159/000201403
8. Kölby L., Persson G., Franzen S., Ahrén B. Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours. Journal of British Surgery. 2003. 90 (6). P. 687–693. DOI: 10.1002/bjs.4149.
9. Fazio N., de Braud F., Delle Fave G., Oberg K. Interferon- and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Annals of Oncology. 2006. 18 (1). P. 13–19. DOI: 10.1093/annonc/mdl144.
10. Raymond E., Dahan L., Raoul J. L. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011. 364 (6). P. 501–513. DOI: 10.1056/NEJMoa1003825.
11. Capdevila J., Sevilla I., Alonso V., Aparicio L. A., Fonseca P. J., Grande E. et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumors in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015. 15 (495) P. 1–11. DOI: 10.1186/s12885–015–1512–6.
12. Bajetta E., Catena L., Fazio N., Pusceddu S., Biondani P., Blanco G. et al. Everolimus in combination with octreotide long-acting repeatable in a firstline setting for patients with neuroendocrine tumors: An ITMO group study. Cancer. 2014. 120 (16). P. 2457–2463. DOI: 10.1002/cncr.287 26.
13. Yao J. C., Shah M. H., Ito T. et al. RAD 001 in Advanced neuroendocrine Tumors, 3 Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011. 364 (6). P. 514–23. DOI: 10.1056/NEJMoa1009290.
14. Panzuto F., Rinzivillo M., Fazio N. et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014. 19 (9). P. 966–974. DOI: 10.1634/theoncologist.2014–0037.
15. Kamp K., Gumz B., Feelders R. A. et al. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177) Lu-octreotate. Endocr Relat Cancer. 2013. 20 (6). P. 825–831. DOI: 10.1530/ ERC-13–0254.
16. Orel N. F., Artamonova E. V., Gorbunova V. A., Delektorskaya V. V., Emel’yanova G.S., Lubimova N. V. et al. Practical recommendations for the drug treatment of neuroendocrine tumors of the gastrointestinal tract, pancreas and other localizations (in English). Malignant tumors: Practi- cal recommendations RUSSCO. 2020; 10 (3s2): 524–537. DOI: 10.18027/2224–5057–2020–10–3s2–30.
Review
For citations:
Androsova A.V., Orlova R.V., Ivanova A.K., Belyak N.P., Kutukova S.I., Kaledina E.A. Clinical and epidemiological features of neuroendocrine tumors on basis of single-centre registry. Medical alphabet. 2022;1(5):7-14. (In Russ.) https://doi.org/10.33667/2078-5631-2022-5-7-14
Views:
263
Email this article 